139:), where the virus replicates only in cells that are dividing - in other words, cancer cells left over in the margin and immune cells that are present. Flucytosine is then administered to the person, and is converted to 5-fluorouracil in those cells by CD expressed by cells that had been infected with the gene therapy vector.
135:; vocimagene amiretrorepvec is intended to be injected into the tissues lining the hole where the tumor was (this region is called the
263:
143:
189:""Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma"
117:
98:
Vocimagene amiretrorepvec (also known as Toca 511) is a gene therapy agent, wherein the payload is a gene encoding
42:
125:
30:
142:
By July 2017, the EMA had granted the combination priority review status, and the FDA had granted it
132:
99:
210:
154:
200:
150:
designation for recurrent HGG, and an orphan designation for the treatment of glioblastoma.
136:
84:
205:
188:
147:
121:
17:
257:
162:
103:
88:
47:
231:
158:
109:
59:
54:
113:
214:
92:
131:
The combination drug was designed to be used after a brain tumor is
157:
and as of July 2017 phase 2/3 trials were underway for recurrent
232:"Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen"
124:(5-FU), a cancer drug. 5-Fluorouracil does not cross the
112:(also known as 5-fluorocytosine, 5-FC, and Toca FC) is an
182:
180:
178:
70:
65:
53:
41:
36:
95:. It is a candidate drug to treat brain cancers.
187:Strebe JK, Lubin JA, Kuo JS (December 2016).
8:
29:
204:
116:drug. It is used in an extended-release
153:The combination is under development by
174:
226:
224:
28:
81:Vocimagene amiretrorepvec/flucytosine
31:Vocimagene amiretrorepvec/flucytosine
7:
206:10.1227/01.neu.0000508605.38694.fd
25:
102:(CD) in a replicating, non-lytic
238:. Springer Nature Switzerland AG
144:Breakthrough Therapy Designation
120:. Flucytosine is a prodrug of
1:
128:well, but flucytosine does.
280:
264:Experimental cancer drugs
161:and recurrent high grade
43:Vocimagene amiretrorepvec
18:Toca 511 & Toca FC
74:Toca 511 and Toca FC
126:blood–brain barrier
83:is an experimental
33:
133:removed surgically
100:cytosine deaminase
104:retroviral vector
78:
77:
16:(Redirected from
271:
248:
247:
245:
243:
228:
219:
218:
208:
184:
85:combination drug
34:
32:
21:
279:
278:
274:
273:
272:
270:
269:
268:
254:
253:
252:
251:
241:
239:
230:
229:
222:
186:
185:
176:
171:
23:
22:
15:
12:
11:
5:
277:
275:
267:
266:
256:
255:
250:
249:
220:
199:(6): N18–N20.
173:
172:
170:
167:
148:FDA Fast Track
122:5-fluorouracil
76:
75:
72:
68:
67:
63:
62:
57:
51:
50:
45:
39:
38:
37:Combination of
24:
14:
13:
10:
9:
6:
4:
3:
2:
276:
265:
262:
261:
259:
237:
233:
227:
225:
221:
216:
212:
207:
202:
198:
194:
190:
183:
181:
179:
175:
168:
166:
164:
160:
156:
151:
149:
145:
140:
138:
134:
129:
127:
123:
119:
115:
111:
107:
105:
101:
96:
94:
90:
86:
82:
73:
69:
66:Clinical data
64:
61:
58:
56:
52:
49:
46:
44:
40:
35:
27:
19:
240:. Retrieved
235:
196:
193:Neurosurgery
192:
163:glioblastoma
152:
141:
130:
108:
97:
91:agent and a
89:gene therapy
87:involving a
80:
79:
48:Gene therapy
26:
236:AdisInsight
159:astrocytoma
118:formulation
110:Flucytosine
71:Other names
60:Cancer drug
55:Flucytosine
169:References
114:antifungal
242:29 August
258:Category
215:27861411
155:Tocagen
93:prodrug
213:
137:margin
244:2017
211:PMID
146:and
201:doi
260::
234:.
223:^
209:.
197:79
195:.
191:.
177:^
165:.
106:.
246:.
217:.
203::
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.